A relevant number of studies performed both in vitro and in vivo on various typologies of tumors (melanoma, thyroid papillary carcinoma, T-cell lymphoma, neuroblastoma, etc.), demonstrated the increased level of β3-ARs and their involvement in the previously described adaptative mechanisms, as well as the beneficial effect of selective β3-AR antagonism [9]. This evidence concerns the gene ADRB3 and melanoma.